Jilin Province Xidian Pharmaceutical Inc. (301130)
Market Closed
11 Aug, 06:57
XSHE XSHE Primary ¥
25. 39
-0.19
-0.7428%
¥
2.35B Market Cap
- P/E Ratio
1.04% Div Yield
1.07M Volume
- Eps
¥ 25.58
Previous Close Want to track 301130 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
301130 closed today lower at ¥25.39, a decrease of -0.7428% from yesterday's close, completing a monthly increase of 5.8799% or ¥1.41. Over the past 12 months, 301130 stock lost -11.0371%.
301130 pays dividends to its shareholders, with the most recent payment made on Jun 01, 2026. The next estimated payment will be in In 9 months on Jun 01, 2027 for a total of ¥0.145.
The last earnings report, released on May 23, 2025, exceeded the consensus estimates by 0.1084%. On average, the company has surpassed earnings expectations by 0.1411%, based on the last three reports.
Jilin Province Xidian Pharmaceutical Inc. has completed 2 stock splits, with the recent split occurring on Apr 11, 2022.
The company's stock is traded on one exchange.
Jilin Province Xidian Pharmaceutical Inc. (301130) FAQ
What is the stock price today?
The current price is ¥25.39.
On which exchange is it traded?
Jilin Province Xidian Pharmaceutical Inc. is listed on XSHE.
What is its stock symbol?
The ticker symbol is 301130.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 1.04%.
What is its market cap?
As of today, the market cap is 2.35B.
Has Jilin Province Xidian Pharmaceutical Inc. ever had a stock split?
Jilin Province Xidian Pharmaceutical Inc. had 2 splits and the recent split was on Apr 11, 2022.
Jilin Province Xidian Pharmaceutical Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Jun Zhang CEO | XSHE Exchange | CNE1000058C4 ISIN |
| CN Country | 320 Employees | 1 Jun 2026 Last Dividend | 11 Apr 2022 Last Split | - IPO Date |
Overview
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd is a prominent company based in Panshi, China. Founded in 1990, the company has established a strong presence in the Chinese pharmaceutical industry focusing on the research and development, production, and sale of chemical raw materials and pharmaceutical preparations. It is dedicated to addressing a range of health issues through its innovative drugs, aiming to improve patient outcomes in various therapeutic areas including anemia, mental disorders, cardiovascular and cerebrovascular diseases, and tumors.
Products and Services
- Drugs for Anemia: The company provides a range of pharmaceutical products designed to treat anemia, a condition characterized by a deficiency of red cells or hemoglobin in the blood, leading to pallor and weariness.
- Mental Disorder Treatments: Recognizing the complexity of mental health issues, Xidian Pharmaceutical offers drugs aimed at treating various mental disorders, contributing to the wellbeing of patients dealing with these conditions.
- Cardiovascular and Cerebrovascular Disease Medications: With a focus on heart and brain health, the company develops medications intended to treat diseases related to the cardiovascular and cerebrovascular systems, targeting conditions that can lead to heart attacks, strokes, and other serious health issues.
- Tumor Treatments: In response to the global challenge of cancer, Xidian Pharmaceutical is actively engaged in providing treatments for tumors, aiming to reduce the burden of this disease and improve the quality of life for patients affected by various forms of cancer.
- Tablets and Capsules: The company's pharmaceutical offerings are available in the convenient forms of tablets and capsules, ensuring ease of use for patients and maximizing the effectiveness of the treatment.
Contact Information
Address: No.777, West Point Street, Panshi, China, 132300
Phone: 86 32 6588 8277
Website: https://xidianyy.com
